Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

183 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents.
Hayden FG, Sugaya N, Hirotsu N, Lee N, de Jong MD, Hurt AC, Ishida T, Sekino H, Yamada K, Portsmouth S, Kawaguchi K, Shishido T, Arai M, Tsuchiya K, Uehara T, Watanabe A; Baloxavir Marboxil Investigators Group. Hayden FG, et al. Among authors: hurt ac. N Engl J Med. 2018 Sep 6;379(10):913-923. doi: 10.1056/NEJMoa1716197. N Engl J Med. 2018. PMID: 30184455 Free article. Clinical Trial.
Antiviral resistance during the 2009 influenza A H1N1 pandemic: public health, laboratory, and clinical perspectives.
Hurt AC, Chotpitayasunondh T, Cox NJ, Daniels R, Fry AM, Gubareva LV, Hayden FG, Hui DS, Hungnes O, Lackenby A, Lim W, Meijer A, Penn C, Tashiro M, Uyeki TM, Zambon M; WHO Consultation on Pandemic Influenza A (H1N1) 2009 Virus Resistance to Antivirals. Hurt AC, et al. Lancet Infect Dis. 2012 Mar;12(3):240-8. doi: 10.1016/S1473-3099(11)70318-8. Epub 2011 Dec 18. Lancet Infect Dis. 2012. PMID: 22186145 Review.
Second isirv antiviral group conference: overview.
Hurt AC, Ison MG, Hayden FG, Hay AJ. Hurt AC, et al. Influenza Other Respir Viruses. 2013 Nov;7 Suppl 3(Suppl 3):1-7. doi: 10.1111/irv.12207. Influenza Other Respir Viruses. 2013. PMID: 24215376 Free PMC article. No abstract available.
Influenza antivirals currently in late-phase clinical trial.
Koszalka P, Tilmanis D, Hurt AC. Koszalka P, et al. Among authors: hurt ac. Influenza Other Respir Viruses. 2017 May;11(3):240-246. doi: 10.1111/irv.12446. Epub 2017 Feb 28. Influenza Other Respir Viruses. 2017. PMID: 28146320 Free PMC article. Review.
Treatment-Emergent Influenza Variant Viruses With Reduced Baloxavir Susceptibility: Impact on Clinical and Virologic Outcomes in Uncomplicated Influenza.
Uehara T, Hayden FG, Kawaguchi K, Omoto S, Hurt AC, De Jong MD, Hirotsu N, Sugaya N, Lee N, Baba K, Shishido T, Tsuchiya K, Portsmouth S, Kida H. Uehara T, et al. Among authors: hurt ac. J Infect Dis. 2020 Jan 14;221(3):346-355. doi: 10.1093/infdis/jiz244. J Infect Dis. 2020. PMID: 31309975 Clinical Trial.
Global update on the susceptibilities of human influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2017-2018.
Takashita E, Daniels RS, Fujisaki S, Gregory V, Gubareva LV, Huang W, Hurt AC, Lackenby A, Nguyen HT, Pereyaslov D, Roe M, Samaan M, Subbarao K, Tse H, Wang D, Yen HL, Zhang W, Meijer A. Takashita E, et al. Among authors: hurt ac. Antiviral Res. 2020 Mar;175:104718. doi: 10.1016/j.antiviral.2020.104718. Epub 2020 Jan 28. Antiviral Res. 2020. PMID: 32004620 Free article.
183 results